Measurement of Reverse Triiodothyronine Level and the Triiodothyronine to Reverse Triiodothyronine Ratio in Dried Blood Spot Samples at Birth May Facilitate Early Detection of Monocarboxylate Transporter 8 Deficiency

Hideyuki Iwayama,1 Hiroki Kakita,2 Masumi Iwasa,1 Shinsuke Adachi,3 Kyoko Takano,4 Masahiro Kikuchi,5 Yasuko Fujisawa,6 Hitoshi Osaka,7 Yasumasa Yamada,2 Akihisa Okumura,1 Khemraj Hirani,8 Roy E. Weiss,8 and Samuel Refetoff9,i

Background: Monocarboxylate transporter 8 (MCT8) deficiency is an X-chromosome-linked neurodevelopmental disorder resulting from impaired thyroid hormone transport across the cell membrane. The diagnosis of MCT8 deficiency is typically delayed owing to the late appearance of signs and symptoms as well as the inability of standard biomarkers of neonatal screening to provide early detection. In this study, we report, for the first time, the ability to detect MCT8 deficiency at birth using dried blood spot (DBS) samples.

Methods: We retrospectively measured triiodothyronine (T3), thyroxine (T4), and reverse T3 (rT3) levels in DBS samples obtained at 4–5 days of life from 6 infants with genetically confirmed MCT8 deficiency and from 110 controls. The latter consisted of 58 healthy term neonates obtained at the same time, 16 were stored for more than 1 year before measurement to match samples from the MCT8-deficient infants. Ten DBS samples were collected at day 1 of life and 42 samples were from prematurely born neonates. Measurements were carried out in extract from eight millimeters diameter DBS using liquid chromatography-tandem mass spectrometry.

Results: Contrary to characteristic iodothyronine abnormalities of MCT8 deficiency during later life, T3 and T4 values were not discriminatory from those of other study groups. In contrast, rT3 was significantly lower. The T3/rT3 ratio was higher in the DBS samples from the MCT8-deficient infants compared with all other groups with no overlap (\(p<0.0001\)).

Conclusions: rT3 and T3/rT3 ratio in DBS samples obtained from neonates can serve as biomarkers to detect MCT8 deficiency at birth.

Keywords: dried blood spot, LC-MS/MS, MCT8 deficiency, newborn screening, reverse T3

Introduction

Monocarboxylate transporter 8 (MCT8) deficiency (OMIM 300095) is an inherited disorder that causes severe psychoneuromotor defects with characteristic abnormalities in serum thyroid hormone (TH) function tests (1). It is caused by mutations in the MCT8 (SLC16A2) gene, on Xq13.2, which impair the transport of TH into the brain, producing the psychoneuromotor abnormalities. However, excess TH available to peripheral tissues, through alternative TH transporters, produces hypermetabolism. The former abnormalities consist of early poor head control and truncal hypotonia,

Departments of 1Pediatrics and 2Perinatal and Neonatal Medicine, School of Medicine, Aichi Medical University, Nagakute, Japan.
3Department of Pediatrics, Fukuchiymia City Hospital, Kyoto, Japan.
4Center for Medical Genetics, Shinshu University Hospital, Nagano, Japan.
5Department of Pediatrics, Hitachi General Hospital, Hitachi, Japan.
6Department of Pediatrics, School of Medicine, Hamamatsu University, Hamamatsu, Japan.
7Department of Pediatrics, Ichi Medical School, Shimosuke, Japan.
8Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
9Departments of Medicine, Pediatrics and Committee on Genetics, The University of Chicago, Chicago, Illinois, USA.
iORCID ID (https://orcid.org/0000-0003-0164-8231).

© Hideyuki Iwayama et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
followed by inability to stand or walk, absent speech, abnormal involuntary movements, and spastic quadriplegia. These signs are not evident until later in life, and given the X-chromosome linked inheritance, carrier mothers are asymptomatic.

In children aged four months or more, TH abnormalities consist of high serum triiodothyronine (T3), low normal thyroxine (T4), and low reverse T3 (rT3) with normal or slightly elevated thyrotropin (TSH). Although this combination of thyroid hormone abnormalities is characteristic of MCT8 deficiency, current neonatal detection programs will not detect affected newborns. Current screening programs only measure TSH and/or T4 and will miss the high T3 and low rT3. As carrier females are asymptomatic and do not have the characteristic TH test abnormalities, prenatal diagnosis is practicable only in those women who have previously given birth to an affected child. Newborns of women not known to be carriers of an MCT8 gene mutation may harbor embryos with a de novo mutation, which will not be identified until neurodevelopmental abnormalities are identified later in infancy or even childhood. This is unfortunate as a recent trial with the thyroid analogue Triac suggested that early treatment is more likely to be effective in improving or preventing the evolution of the neuromotor deficit (2).

While the thyroid tests abnormalities in MCT8 deficiency are virtually pathognomonic in both humans (1) and in mice (3,4), this may not be the case at birth. Indeed, at birth, Mct8-deficient mice have higher rather than lower serum T4 concentration and undetectably low T3 (5). Thus, we performed a retrospective pilot study to determine the nature of iodothyronine abnormalities in the first five days of life and to assess whether they could be used in the early detection of MCT8 deficiency.

In this retrospective study, we measured T3, T4, and rT3 levels in dried blood spot (DBS) samples obtained from newborns later confirmed genetically to have MCT8 deficiency. Results were compared with those from DBS samples obtained from normal controls at 1–6 days of life, in prematurely born, and in samples stored up to 2 years. To the best of our knowledge, this is the first study that measured T3 and rT3 levels in DBS specimens obtained in the first week of life. Our findings provide promising biomarkers for the early detection of MCT8 deficiency and a possible means to determine the prevalence of this devastating condition.

Materials and Methods

Subjects

In Japan, DBS samples are obtained from all neonates at 4–5 days of life as part of mass screening program for inborn errors of metabolism. All DBS samples in this study had TSH values within the reference range and were not recalled by the respective screening programs. The deidentified residual DBS samples, stored at room temperature, were used for our studies. There were six samples from infants with genetically confirmed MCT8 deficiency [c.733G>T (p.R245X); c.1556C>A (S519L); c.883G>A (p.G295S); c.985_986insG (p.Asp329Glyfs*1); c.661G>A (p.G221R); and c.1188_1189insG (p.Asp397Hisfs*57); amino acids numbered according to the long form of the MCT8 protein]. As controls, 110 DBS samples were obtained consisting of healthy neonates, 16 of which were measured after storage for more than a year. In addition, 10 DBS samples were obtained from healthy infants born at term but collected at the end of the 1st day of life, as this is sometimes the practice in the United States for neonates and mothers discharged 1 day postpartum. Of the total of 106 DBS samples, 88 were collected in Japan and 18 in the United States. The same filter paper was used. Details on demographics including gestational age, sex, birth weight, and duration of sample storage before analysis are provided in Supplementary Table S1. The study was approved by the ethical committees and institutional review boards of the three involved institutions (Aichi Medical University, 2015-H359; Universities of Miami and Chicago, 20200996). A written informed consent was obtained from the parents of all study subjects. All study evaluations and procedures were performed in accordance with the Declaration of Helsinki.

Methods

T3, T4, and rT3 were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously (6). It was based on the LC-MS/MS method used in mouse serum and tissues, and results were in agreement with those obtained by radioimmunoassay (5). The LC-MS/MS method was modified for use in DBS samples (for details see Supplemental Data).

Statistical analysis

T3, T4, and rT3 levels are expressed as mean ± standard deviation (SD). Statistical analysis using analysis of variance with Dunnett’s test for comparison of differences between all five groups was performed at Aichi Medical University and results were confirmed at the University of Chicago.

Results

The demographics of the two groups are given in Supplementary Table S1. These were not significantly different with respect to gestational age or birth weight except for the group of prematurely born. The same table provides information regarding age at blood sampling and the time elapsed from sampling to analysis. As storage is expected to produce iodothyronine degradation (7) by deiodination, a group of DBS samples obtained from normal infants but stored for 1.1–2.2 years were included to match the stored DBS samples to the MCT8-deficient group.

Results of the study are presented in Figures 1 and 2, and mean values ± SD are provided in Table 1. The concentrations of T3, T4, and T3 are shown in Figure 1A–C. The T3 concentrations of the MCT8-deficient newborns were significantly lower than the other group, except for those of the normal infants. The concentration of T4 was also not significantly different than the other group, except for those of the normal infants. The concentration of T4 was also not significantly different than the other group, except for those of the normal infants. The concentration of T4 was also not significantly different than the other group, except for those of the normal infants. (Fig. 1C; Table 1). The concentration of rT3 in the MCT8-deficient newborns were significantly lower than that of all other groups (Fig. 1B; mean values ± SD in Table 1). The concentration of T4 was also not significantly different than the other group, except for those of the normal infants. (Fig. 1C; Table 1).
Of note, the T3/T4 ratios between the MCT8-deficient group and the corresponding matched normal controls of newborns, whose DBS samples were stored for more than 1 year, completely overlapped (Fig. 2B). Ratios of T3/(rT3 + T4) (not shown) did not give better discriminatory results.

**Discussion**

Currently, most neonatal screening programs are based on measurement of TSH only in DBS samples and, therefore, have not detected newborns with MCT8 deficiency. Programs that also measure T4, total or free, have picked up the low concentration in some newborns with MCT8 deficiency. This led in some instances to treatment with physiological doses of levothyroxine, with no beneficial effects (8,9). In fact 6 and 4 of 8 DBS samples from newborns with MCT8 deficiency had total T4 values that were 1 and 2 SDs, respectively, below the mean value (10). In another report of 8 MCT8-deficient newborn, the mean total T4 was 5.1 ± 1.6 μg/dL with a range of 3.1–8.4, compared with a reference range of 6–15 μg/dL (11).

Serum TH tests abnormalities in older infants, children, and adults with MCT8 deficiency are typical if not fully pathognomonic. However, it could not be construed that this will also be the case in the first few days of life, given their immature livers, and the contribution of other tissues to the metabolism of TH affecting serum TH concentrations. Based on studies in adult mice with Mct8 deficiency, serum T4 is low due to the combination of reduced secretion from the thyroid gland, increased consumptive degradation by deiodinase 1, and increased excretion in urine (12,13). Serum T3 is increased owing to the increased conversion of T4 to T3 by deiodinases 1, its decreased degradation by low deiodinase 3 activity, and, to some extent, reduced transport into tissues (3,4). The high deiodinase 1 and low deiodinase 3 activity contribute to the markedly reduced rT3 (14). While Mct8-deficient mice manifest the same abnormalities as humans during adulthood, this is not the case in the early postnatal life. Postpartum low rT3 is the first to manifest, followed by low T4, high TSH, and only then high T3 (3,5). However, in humans with MCT8 deficiency, the TH abnormalities during the first few days of life remained unknown until this study. Thus, the primary aim of this study was to determine the nature of iodothyronine abnormalities in the first week of life.

To the best of our knowledge, this is the first study that has measured T3 and rT3 levels in DBS samples obtained at birth. MCT8-deficient newborns showed significantly decreased rT3 and T4 compared to normal newborns. Measurement of T3 in the MCT8 deficient newborns was not significant from normal newborns as the elevated T3 is seen only in later life.
This is not surprising as T3 is maintained low in the fetus. However, the rT3, normally elevated at birth, was significantly reduced in MCT8-deficient newborns. More importantly the ratios of T3/rT3 and T3/(rT3 $\cdot$ T4) were lower and with no overlap with all other groups (Fig. 2). The values of the latter two in control, compared with MCT8-deficient newborns, did not overlap (Fig. 1). This suggests that these biomarkers could have 100% sensitivity and specificity for the detection of newborns with MCT8 deficiency.

Newborns T4 and FT4 concentrations can be low in prematurity, critical illness, thyroglobulin deficiency, and in infants born to thyrotoxic mothers as well as in congenital central hypothyroidism (15,16). In contrast, in embryonic fluids and at birth, T3 is low and rT3 is high (17,18). In congenital central hypothyroidism, both T3 and rT3 are low (18). Thus, measurement of all three iodothyronines may be necessary to identify newborns with MC8 deficiency. LC-MS/MS provides these results at the same time without additional effort or cost.

The key prerequisites for an effective neonatal screening program include adequate knowledge of the natural history, availability of methods for early diagnosis, and effective treatment to improve prognosis (19). The natural history of MCT8 deficiency is well known (10). This study provides

![Graph showing T3/rT3, T3/T4, and T3/(rT3 $\cdot$ T4) ratios in individual DBS samples in groups identified on the bottom of each panel.](image)

**FIG. 2.** Calculated T3/rT3 (A), T3/T4 (B), and T3/(rT3 $\cdot$ T4) (C) ratios in individual DBS samples in groups identified on the bottom of each panel. $p$-Values obtained by comparisons using ANOVA between samples from MCT8-deficient and each other group are given on top of each panel. The $p$-values of differences between the samples from normal neonates one of which was stored for more than 1 year (1.1–2.3 years) are also shown. Open circles identify samples collected in Japan and closed circles identify samples collected in the United States.

| Group                      | N  | T3 (ng/dL) | rT3 (ng/dL) | T4 (mcg/dL) | T3/rT3 | T3/T4 | T3/(rT3 $\cdot$ T4) |
|---------------------------|----|------------|-------------|-------------|--------|-------|---------------------|
| MCT8 deficient            | 6  | 94±18      | 32±7        | 9.3±2.2     | 3.04±0.67 | 10.1±2.3 | 0.349±0.146        |
| Normal infants            | 42 | 76±21      | 78±20       | 15.7±3.6    | 1.02±0.34 | 20.5±4.7 | 0.067±0.027        |
| Normal infants (DBS stored $>$1 year) | 16 | 119±42     | 130±47      | 8.7±2.1     | 0.96±0.31 | 7.8±2.2  | 0.117±0.049        |
| Prematurely born          | 34 + [8] | 57±30      | 131±56      | 7.9±3.1     | 0.50±0.35 | 21.1±18.4 | 0.071±0.063        |
| Normal infants (DBS collected at day 1) | [10] | 80±22      | 137±55      | 9.2±3.0     | 0.64±0.20 | 11.8±3.8 | 0.075±0.031        |

Numbers in square brackets are samples from the United States.

DBS, dried blood spot; MCT8, monocarboxylate transporter 8; N, number of DBS; rT3, reverse T3; SD, standard deviation; T3, triiodothyronine; T4, thyroxine.
a basis for the development of neonatal screening test for MCT8 deficiency. The use of LC-MS/MS in routine clinical diagnosis is gaining popularity and has already become the preferred method in the measurements of serum testosterone and thyroglobulin. With reduction in cost of LC-MS/MS measurement and the increase in survival and cost for the care of individuals with MCT8 deficiency, the application of LC-MS/MS in neonatal screening is possible. Although current treatments of MCT8 deficiency are at best palliative, more effective early treatment using TH analogues (2) and gene-directed treatments are under development (11,20).

In conclusion, measurement of rT3 and the T3/rT3 ratio in DBS samples at birth are useful for early detection of MCT8 deficiency and will help determine the prevalence of this condition.

Acknowledgment

We thank Masatsune Itoh from Kanazawa Medical University for the genetic analysis of MCT8.

Authors’ Contributions

H.I. designed the research project, interpreted the results, and wrote the initial version of the article. H.K., S.A., K.T., M.K., Y.F., H.O., Y.Y., and K.H. contributed to the acquisition of samples. M.I. was a major contributor in the measurement of iodothyronines by LC-MS/MS. A.O. and R.E.W. reviewed the data and critically revised the article for its scientific content. S.R. advised in setting LC-MS/MS conditions and had a major role in preparation of the article. All authors read and approved the final article.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

The research of H.I. was supported by JSPS KAKENHI, Grant Nos. 16K19676 and 18K15691, The Nitto Foundation, Aichi Medical University “Aikei-Kai” Foundation, The Japanese Society for Pediatric Endocrinology Future Development Grant, and Yoshiko and Seizo Foundation. S.R. was supported, in part, by Grant No. DK15070 from the National Institutes of Health, USA. and R.E.W. by funds from the Esformes Thyroid Research Fund.

Supplementary Material

Supplementary Data
Supplementary Table S1

References

1. Groeneweg S, van Geest FS, Peeters RP, Heuer H, Visser WE 2020 Thyroid hormone transporters. Endocr Rev 41: 1–56.
2. Groeneweg S, Peeters RP, Moran C, Stoupa A, Auriol F, Tonduti D, Dica A, Paone L, Rozenkova K, Malikova J, van der Walt A, de Coo IFM, McGowan A, Lyons G, Aarsen FK, Barca D, van Beynum IM, van der Knoop MM, Jansen J, Manshade M, Lunsing RJ, Nowak S, den Uil CA, Zilnikens MC, Visser FE, Vrijmoeth P, de Wit MCY, Wolf NI, Zandstra A, Ambegaonkar G, Singh Y, de Rijke YB, Medici M, Bertini ES, Depoorter S, Lebl J, Cappa M, De Meirleir L, Krude H, Craiu D, Zibordi F, Oliver Petit I, Polak M, Chatterjee K, Visser TJ, Visser WE 2019 Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:695–706.
3. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S 2006 Tissue specific thyroid hormone deprivation and excess in Mct8 deficient mice. Endocrinology 147:4036–4043.
4. Trajkovic M, Visser TJ, Mattig J, Horn S, Lukas J, Darras VM, Raivich G, Bauer K, Heuer H 2007 Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest 117:627–635.
5. Ferrara AM, Liao XH, Gil-Ibanez P, Marcinkowski T, Bernal J, Weiss RE, Dumitrescu AM, Refetoff S 2013 Changes in thyroid status during perinatal development of MCT8-deficient male mice. Endocrinology 154:2533–2541.
6. Iwayama H, Sugahara K, Nakano M, Minoru F, Okumura A 2017 Measurement of reverse triiodothyronine levels using liquid chromatography-tandem mass spectrometry in the serum of 89 outpatients. Med Mass Spec 1:10–13.
7. Bourdoux PP, Van Thi HV, Courtois PC, Ermmans AM 1990 Superiority of thyrotropin to thyroxine as a tool in the screening for congenital hypothyroidism by the filter paper spot technique. Clin Chim Acta 195:97–106.
8. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S 2004 A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 74: 168–175.
9. Friesema EC, Grueters A, Biebermann H, Krude H, van Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP, Visser TJ 2004 Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 364: 1435–1437.
10. Groeneweg S, van Geest FS, Abaci A, Alcantud A, Ambegaonkar GP, Armour CM, Bakhtiani P, Barca D, Bertini ES, van Beynum IM, Brunetti-Pierri N, Bugiani M, Cappa M, Cappuccio G, Castellotti B, Castiglioni C, Chatterjee K, de Coo IFM, Coutant R, Craiu D, Crock P, DeGoede C, Demir K, Dica A, Dimitri P, Dolcetta-Capuzzo A, Dremmen MHG, Dubey R, Enderli A, Fairech J, Gallichan J, George B, Gevers EF, Hackenberg A, Halasz Z, Heinrich B, Huyah T, Klowski A, van der Knap MS, van der Knoop MM, Konrad D, Kooken DA, Krude H, Lawson-Yuen A, Lebl J, Linder-Lucht M, Lorea CF, Lourenco CM, Lunsing RJ, Lyons G, Malikova J, Mancilla EE, McGowan A, Mencic Y, Lora FM, Moran C, Muller KE, Oliver-Petit I, Paone L, Paul PG, Polak M, Porta F, Poswar FO, Reinauer C, Rozenkova K, Menevse TS, Simm P, Simon A, Singh Y, Spada M, van der Spek J, Stals MAM, Stoupa A, Subramanian GM, Tonduti D, Turan S, den Uil CA, Vanderniet J, van der Walt A, Wemeau JL, Wierzbja J, de Wit MY, Wolf NI, Wurm M, Zibordi F, Zung A, Zwaveling-Soonawala N, Visser WE 2020 Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 8:594–605.
11. Refetoff S, Pappa T, Williams MK, Matheus MG, Liao X-H, Hansen K, Nicol L, Pierce M, Blasco PA, Wiebers
Jensen M, Bernal J, Weiss RE, Dumitrescu AM, LaFranchi SH 2021 Prenatal treatment of thyroid hormone cell membrane transport defect caused by MCT8 gene mutation. Thyroid 31:713–720.

12. Di Cosmo C, Liao XH, Dumitrescu AM, Philp NJ, Weiss RE, Refetoff S 2010 Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. J Clin Invest 120:3377–3388.

13. Trajkovic-Arsic M, Visser TJ, Darras VM, Friesema EC, Schlott B, Mittag J, Bauer K, Heuer H 2010 Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice. Endocrinology 151:802–809.

14. Liao XH, Di Cosmo C, Dumitrescu AM, Hernandez A, Van Sande J, St Germain DL, Weiss RE, Galton VA, Refetoff S 2011 Distinct roles of deiodinases on the phenotype of Mct8 defect: a comparison of eight different mouse genotypes. Endocrinology 152:1180–1191.

15. Soneda A, Adachi M, Muroya K, Asakura Y, Yamagami Y, Hirahara F 2014 Overall usefulness of newborn screening for congenital hypothyroidism by using free thyroxine measurement. Endocr J 61:1025–1030.

16. Zwaveling-Soonawala N, van Trotsenburg ASP, Verkerk PH 2018 TSH and FT4 concentrations in congenital central hypothyroidism and mild congenital thyroidal hypothyroidism. J Clin Endocrinol Metab 103:1342–1348.

17. Contempre B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, Morreale de Escobar G 1993 Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. J Clin Endocrinol Metab 77:1719–1722.

18. Faase EM, Meacham LR, Novack CM, Brakin MI, Mosier HD, Culler FL 1997 Decreased reverse T3 levels in neonates with central hypothyroidism. J Perinatol 17:15–17.

19. Ross LF 2006 Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A 140:914–922.

20. Iwayama H, Liao XH, Braun L, Barez-Lopez S, Kaspar B, Weiss RE, Dumitrescu AM, Guadano-Ferraz A, Refetoff S 2016 Adeno associated virus 9-based gene therapy delivers a functional monocarboxylate transporter 8, improving thyroid hormone availability to the brain of Mct8-deficient mice. Thyroid 26:1311–1319.

Address correspondence to:
Hideyuki Iwayama, MD, PhD
Department of Pediatrics
School of Medicine
Aichi Medical University
1-1, Yazakokarimata
Nagakute, Aichi 480-1195
Japan
E-mail: iwahide1976@gmail.com